Select a State

Global health R&D delivers for Virginia

US government investment in global health R&D has delivered

$874.5 million
to Virginia research institutions
9,700+ new jobs
for Virginia

Neglected diseases in Virginia

Chikungunya cases
93
Dengue cases
129
HIV diagnoses
8,673
Malaria cases
484
Tuberculosis cases
2,081
West Nile cases
92
Zika cases
118
--

Virginia's top USG-funded global health R&D institutions

Department of Defense (self-funding and other agency transfers)
$630.2 million
CONRAD
$145.8 million
Virginia Polytechnic Institute and State University (Virginia Tech)
$32.1 million
American Type Culture Collection
$27.6 million
University of Virginia
$21.5 million
US National Science Foundation
$9.3 million
Northrop Grumman Corporation
$3.6 million
Eastern Virginia Medical School
$2.6 million
US Civilian Research and Development Foundation (CRDF Global)
$545 thousand
University of Richmond
$500 thousand
James Madison University
$446 thousand
Ferrum College
$153 thousand
US Systems Research and Application Corporation (now part of CSRA)
$85 thousand
NETE Solutions
$8 thousand

Virginia industry in global health R&D

Celgene
Location(s):
Arlington
CSRA
Location(s):
Falls Church
Cupron
Location(s):
Richmond
Jericho Sciences
Location(s):
Fairfax Station
Luna Innovations
Location(s):
Roanoke
Merck & Co
Location(s):
Elton
NETE Solutions
Location(s):
McLean
Northrop Grumman
Location(s):
Falls Church, Herndon
Parabon NanoLabs
Location(s):
Reston
Thermal Gradient
Location(s):
Richmond
Virongy
Location(s):
Manassas

Virginia's top areas of global health R&D by USG funding

42.8%
HIV/AIDS
25.3%
Malaria
3.8%
Tuberculosis
9.9%
Diarrheal diseases
8.9%
Ebola/viral hemorrhagic fevers
4.5%
Neglected tropical diseases
Buruli ulcer
Dengue
Helminths
Kinetoplastids
Leprosy
4.8%
Other
Bacteria pneumonia & meningitis
Non-allocable
Salmonella infections

Global health R&D at work in Virginia

Many drugs used to treat HIV/AIDS have life-threatening side effects. One new, highly effective drug doesn’t, but it’s extremely expensive to produce. Virginia Commonwealth University is aiming to make it cheaper. Drugs with fewer side effects are important for long-term care of HIV/AIDS patients, who must take the drugs for life. The university has a proven track record for reinventing how drugs are made, resulting in cost-effective products that save lives.

Footnotes